Sanofi-Aventis
The partnership will match Sanofi's money with Harvard's brains in pursuit of new therapies and diagnostics for the three key research arenas. Harvard's Office of Technology Development will bird-dog various projects Sanofi may be interested in, and the pharma giant will host an annual soiree with university researchers to bolster the relationship.
For Sanofi, the pact gives its scientists a chance to work more closely with researchers who have been at the forefront of biomedical research in the U.S. The deal follows a pact that Pfizer
"This collaboration exemplifies Harvard's commitment to creatively partner with industry in ways that we hope will push the boundaries of translational science, and advance our mandate of serving the public interest by making the fruits of our research available to society," says Steven Hyman MD, provost of Harvard University.
This article originally published here. Get your free daily biotech briefing here.
Related Stories: